Stanley J Szefler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5703346/publications.pdf

Version: 2024-02-01

3668 5739 32,212 467 92 167 citations h-index g-index papers 516 516 516 18121 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Electronic medication monitoring versus self-reported use of inhaled corticosteroids and short-acting beta ₂ -agonists in uncontrolled asthma. Journal of Asthma, 2022, 59, 2024-2027.	0.9	8
2	Difficult-to-Treat Asthma Management in School-Age Children. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 359-375.	2.0	15
3	The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions. Journal of Allergy and Clinical Immunology, 2022, 149, 488-516.e9.	1.5	24
4	Prioritising primary care respiratory research needs: results from the 2020 International Primary Care Respiratory Group (IPCRG) global e-Delphi exercise. Npj Primary Care Respiratory Medicine, 2022, 32, 6.	1.1	9
5	Social Determinants of Health in Asthma Through the Life Course. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 953-961.	2.0	17
6	Indoor Dust Bacterial and Fungal Microbiome in Homes of Asthmatic Children from 5 US Cities. Journal of Allergy and Clinical Immunology, 2022, 149, AB83.	1.5	0
7	The National Heart Lung and Blood Institute Disparities Elimination through Coordinated Interventions to Prevent and Control Heart and Lung Disease Alliance. Health Services Research, 2022, 57, 20-31.	1.0	9
8	Applying dissemination and implementation research methods to translate a school-based asthma program. Journal of Allergy and Clinical Immunology, 2022, 150, 535-548.	1.5	4
9	Over-the-Counter Availability of Rescue Inhalers for Asthma. JAMA - Journal of the American Medical Association, 2022, 328, 215.	3.8	0
10	No dose effect observed with chronic fluticasone propionate on growth velocity in children. Pediatric Allergy and Immunology, 2021, 32, 377-381.	1.1	1
11	The Impact of Patient Self-Monitoring Via Electronic Medication Monitor and Mobile App Plus Remote Clinician Feedback on Adherence to Inhaled Corticosteroids: A Randomized Controlled Trial. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1586-1594.	2.0	42
12	Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptation. Contemporary Clinical Trials, 2021, 100, 106228.	0.8	24
13	Possible Protective Effect of Omalizumab on Lung Function Decline in Patients Experiencing Asthma Exacerbations. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1201-1211.	2.0	8
14	The Relationship of Asthma Biologics to Remission for Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1090-1098.	2.0	33
15	Assessing asthma control: comparison of electronic-recorded short-acting beta-agonist rescue use and self-reported use utilizing the asthma control test. Journal of Asthma, 2021, 58, 271-275.	0.9	10
16	Medication adherence was greater in a digital asthma platform consisting of controller and rescue vs. controller inhalers alone. Journal of Allergy and Clinical Immunology, 2021, 147, AB50.	1.5	0
17	Does lung function change in the months after an asthma exacerbation in children?. Pediatric Allergy and Immunology, 2021, 32, 1208-1216.	1.1	2
18	Digital assessment of medication utilization by age and diagnosis of asthma or COPD. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1723-1725.	2.0	4

#	Article	IF	CITATIONS
19	Adherence rates during a randomized controlled trial evaluating the use of blinded acetaminophen and ibuprofen in children with asthma. Contemporary Clinical Trials, 2021, 104, 106334.	0.8	0
20	Factors Associated with Persistence of Severe Asthma from Late Adolescence to Early Adulthood. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 776-787.	2.5	16
21	PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment. Journal of Allergy and Clinical Immunology, 2021, 147, 1594-1601.	1.5	27
22	Digital Health Technology in Asthma: A Comprehensive Scoping Review. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2377-2398.	2.0	54
23	Exacerbation-Prone Asthma: A Biological Phenotype or a Social Construct. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2627-2634.	2.0	13
24	Should children with asthma simply be treated as little adults?. Annals of Allergy, Asthma and Immunology, 2021, 127, 520-521.	0.5	4
25	Response to Omalizumab in Black and White Patients with Allergic Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4021-4028.	2.0	6
26	Ongoing asthma management in children during the COVID-19 pandemic: to step down or not to step down?. Lancet Respiratory Medicine, the, 2021, 9, 820-822.	5.2	4
27	Pharmacogenetic studies of long-acting beta agonist and inhaled corticosteroid responsiveness in randomised controlled trials of individuals of African descent with asthma. The Lancet Child and Adolescent Health, 2021, 5, 862-872.	2.7	10
28	Building Bridges for Asthma Care Program: A School-Centered Program Connecting Schools, Families, and Community Health-Care Providers. Journal of School Nursing, 2020, 36, 168-180.	0.9	23
29	Challenges in managing difficultâ€toâ€treat asthma in children: Stop, look, and listen. Pediatric Pulmonology, 2020, 55, 791-794.	1.0	8
30	Legends of allergy and immunology: Donald Y. M. Leung. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 724-726.	2.7	0
31	Development and initial validation of the Asthma Severity Scoring System (ASSESS). Journal of Allergy and Clinical Immunology, 2020, 145, 127-139.	1.5	19
32	What is a clinically meaningful change in exhaled nitric oxide for children with asthma?. Pediatric Pulmonology, 2020, 55, 599-606.	1.0	8
33	An expert consensus framework for asthma remission as a treatment goal. Journal of Allergy and Clinical Immunology, 2020, 145, 757-765.	1.5	144
34	Addressing the risk domain in the longâ€term management of pediatric asthma. Pediatric Allergy and Immunology, 2020, 31, 233-242.	1.1	16
35	Paradigm Shift in Asthma Therapy for Adolescents. JAMA Pediatrics, 2020, 174, 227.	3.3	7
36	Health navigators are an effective strategy to bridge the gap for school-aged children at risk for asthma disparities. Journal of Allergy and Clinical Immunology, 2020, 145, AB75.	1.5	0

#	Article	IF	Citations
37	Personalized asthma management in pediatric patients based on treatment response. Expert Review of Precision Medicine and Drug Development, 2020, 5, 439-446.	0.4	О
38	The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations. Journal of Biopharmaceutical Statistics, 2020, 30, 1026-1037.	0.4	11
39	Using fractional exhaled nitric oxide to guide step-down treatment decisions in asthma: practical considerations. European Respiratory Journal, 2020, 56, 2002809.	3.1	О
40	Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2673-2680.e3.	2.0	15
41	Heterogeneity of Mild to Moderate Persistent Asthma in Children: Confirmation by Latent Class Analysis and Association with 1-Year Outcomes. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2617-2627.e4.	2.0	21
42	COVID-19 and the impact of social determinants of health. Lancet Respiratory Medicine, the, 2020, 8, 659-661.	5.2	498
43	Disease Burden and Long-Term Risk of Persistent Very Poorly Controlled Asthma: TENOR II. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2243-2253.	2.0	16
44	The Impact of Social Determinants of Health on Children with Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1808-1814.	2.0	78
45	Comparative Responses in Lung Function Measurements with Tiotropium in Adolescents and Adults, and Across Asthma Severities: A Post Hoc Analysis. Pulmonary Therapy, 2020, 6, 131-140.	1.1	2
46	Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis. European Respiratory Journal, 2020, 55, 1902150.	3.1	26
47	A worldwide charter for all children with asthma. Pediatric Pulmonology, 2020, 55, 1282-1292.	1.0	23
48	Oscillometry for acute asthma in the pediatric emergency department. Annals of Allergy, Asthma and Immunology, 2020, 125, 607-609.	0.5	5
49	Forced Expiratory Flow (FEF25–75%) as a Clinical Endpoint in Children and Adolescents with Symptomatic Asthma Receiving Tiotropium: A Post Hoc Analysis. Pulmonary Therapy, 2020, 6, 151-158.	1.1	8
50	Electronic medication monitors help determine adherence subgroups in asthma. Respiratory Medicine, 2020, 164, 105914.	1.3	15
51	Update on the NAEPPCC Asthma Guidelines: The wait is over, or is it?. Journal of Allergy and Clinical Immunology, 2020, 146, 1275-1280.	1.5	7
52	Managing Asthma during Coronavirus Disease-2019: An Example for Other Chronic Conditions in Children and Adolescents. Journal of Pediatrics, 2020, 222, 221-226.	0.9	68
53	Does treatment guided by exhaled nitric oxide fraction improve outcomes in subgroups of children with asthma?. European Respiratory Journal, 2020, 55, 1901879.	3.1	7
54	Asthma attacks in children are always preceded by poor asthma control: myth or maxim?. Breathe, 2020, 16, 200169.	0.6	3

#	Article	IF	Citations
55	Potential Therapeutic Options for Severe Asthma in Children: Lessons from Adult Trials. , 2020, , 287-312.		O
56	Introducing telehealth and adherence monitoring to schoolâ€eentered asthma management. Pediatric Pulmonology, 2020, 55, 565-567.	1.0	1
57	Inaccuracy of asthma-related self-reported health-care utilization data compared to Medicaid claims. Journal of Asthma, 2019, 56, 947-950.	0.9	1
58	Time for Allergists to Consider the Role of Mouse Allergy in Non-Inner City Children with Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1778-1782.	2.0	6
59	Safety of tiotropium Respimat \hat{A}^{\otimes} in black or African-American patients with symptomatic asthma. Respiratory Medicine, 2019, 155, 58-60.	1.3	5
60	Asthma Control—Time to Rethink Definitions and Criteria. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1522-1523.	2.0	0
61	Reply. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2102-2103.	2.0	0
62	Symptoms and perception of airway obstruction in asthmatic patients: Clinical implications for use of reliever medications. Journal of Allergy and Clinical Immunology, 2019, 144, 1180-1186.	1.5	45
63	Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma. New England Journal of Medicine, 2019, 381, 1227-1239.	13.9	44
64	Data Science for Child Health. Journal of Pediatrics, 2019, 208, 12-22.	0.9	22
65	Cost-effectiveness and comparative effectiveness of biologic therapy for asthma. Annals of Allergy, Asthma and Immunology, 2019, 122, 367-372.	0.5	96
66	Response. Chest, 2019, 155, 1313-1314.	0.4	0
67	Tiotropium add-on therapy is safe andÂreduces seasonal worsening in paediatricÂasthma patients. European Respiratory Journal, 2019, 53, 1801824.	3.1	14
68	Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level. New England Journal of Medicine, 2019, 380, 2009-2019.	13.9	95
69	Severe asthma in children and adolescents. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2280-2282.	2.7	4
70	Seasonal variation in asthma exacerbations in the AUSTRI andÂVESTRIÂstudies. ERJ Open Research, 2019, 5, 00153-2018.	1.1	9
71	Novel pediatricâ€automatedÂrespiratory score using physiologic data and machine learning in asthma. Pediatric Pulmonology, 2019, 54, 1149-1155.	1.0	20
72	High-risk asthma. Annals of Allergy, Asthma and Immunology, 2019, 122, 441-442.	0.5	0

#	Article	IF	Citations
73	Tiotropium Is Efficacious in 6- to 17-Year-Olds with Asthma, Independent of T2 Phenotype. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2286-2295.e4.	2.0	27
74	Screening for inhalation technique errors with electronic medication monitors. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2065-2067.	2.0	12
75	Commentary: Treating Pediatric Asthma According Guidelines. Frontiers in Pediatrics, 2019, 7, 109.	0.9	0
76	Asthma: moving toward a global children's charter. Lancet Respiratory Medicine, the, 2019, 7, 299-300.	5.2	7
77	Outcomes for Pediatric Asthmatic Inpatients After Implementation of an Emergency Department Dexamethasone Treatment Protocol. Hospital Pediatrics, 2019, 9, 92-99.	0.6	7
78	A computerized decision support tool to implement asthma guidelines for children and adolescents. Journal of Allergy and Clinical Immunology, 2019, 143, 1760-1768.	1.5	13
79	Challenges in assessing the efficacy of systemic corticosteroids for severe wheezing episodes in preschool children. Journal of Allergy and Clinical Immunology, 2019, 143, 1934-1937.e4.	1.5	2
80	Applying a biopsychosocial model to inner city asthma: Recent approaches to address pediatric asthma health disparities. Paediatric Respiratory Reviews, 2019, 32, 10-15.	1.2	20
81	Can early intervention in pediatric asthma improve longâ€ŧerm outcomes? A question that needs an answer. Pediatric Pulmonology, 2019, 54, 348-357.	1.0	11
82	What Is the Role of Increasing Inhaled Corticosteroid Therapy in Worsening Asthma in Children?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 842-847.	2.0	2
83	Where does worsening asthma end and an asthma exacerbation begin?. Annals of Allergy, Asthma and Immunology, 2019, 123, 329-330.	0.5	2
84	Change in FEV1 and Feno Measurements as Predictors of Future Asthma Outcomes in Children. Chest, 2019, 155, 331-341.	0.4	47
85	Reply. Journal of Pediatrics, 2019, 204, 328-329.	0.9	0
86	Building Bridges for Asthma Care: Reducing school absence for inner-city children with health disparities. Journal of Allergy and Clinical Immunology, 2019, 143, 746-754.e2.	1.5	33
87	Phenotypes of Recurrent Wheezing in Preschool Children: Identification by Latent Class Analysis and Utility in Prediction of Future Exacerbation. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 915-924.e7.	2.0	47
88	Quantifying beta-agonist utilization: Occasions or puffs?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1088-1090.	2.0	2
89	Racial Disparities in Asthma-Related Health Outcomes in Children with Severe/Difficult-to-Treat Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 568-577.	2.0	42
90	Feasibility of medication monitoring sensors in high risk asthmatic children. Journal of Asthma, 2019, 56, 270-272.	0.9	11

#	Article	IF	CITATIONS
91	Severe asthma: mechanisms in children. , 2019, , 231-245.		2
92	The Composite Asthma Severity Index: A Tool for Assessing Impact of Omalizumab Treatment in Children with Moderate-to-Severe Persistent Allergic Asthma. Journal of Allergy and Clinical Immunology, 2018, 141, AB100.	1.5	2
93	Asthma across the lifespan: Time for a paradigm shift. Journal of Allergy and Clinical Immunology, 2018, 142, 773-780.	1.5	31
94	Challenges in the treatment of asthma in children and adolescents. Annals of Allergy, Asthma and Immunology, 2018, 120, 382-388.	0.5	35
95	Greater Treatment Benefit with Omalizumab in Children with Increased Asthma Severity: Exploratory Analyses from the Inner-City Anti-IgE Therapy for Asthma (ICATA) Study. Journal of Allergy and Clinical Immunology, 2018, 141, AB14.	1.5	10
96	The pediatric asthma yardstick. Annals of Allergy, Asthma and Immunology, 2018, 120, 559-579.e11.	0.5	33
97	Controlling the Risk Domain in Pediatric Asthma through Personalized Care. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 036-044.	0.8	4
98	Safety and efficacy of tiotropium in children aged $1\hat{a}\in$ 5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine, the, 2018, 6, 127-137.	5.2	62
99	Efficacy and Safety of Tiotropium in Children and Adolescents. Drugs, 2018, 78, 327-338.	4.9	30
100	Overweight/obesity status in preschool children associates with worse asthma but robust improvement on inhaled corticosteroids. Journal of Allergy and Clinical Immunology, 2018, 141, 1459-1467.e2.	1.5	15
101	Glutathione and arginine levels: Predictors for acetaminophen-associated asthma exacerbation?. Journal of Allergy and Clinical Immunology, 2018, 142, 308-311.e9.	1.5	3
102	More than a decade follow-up in patients with severe or difficult-to-treat asthma: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) II. Journal of Allergy and Clinical Immunology, 2018, 141, 1590-1597.e9.	1.5	62
103	An Analysis of Type 2 Biomarkers in TENOR II. Journal of Allergy and Clinical Immunology, 2018, 141, AB96.	1.5	0
104	Current State and Future of Biologic Therapies in the Treatment of Asthma in Children. Pediatric, Allergy, Immunology, and Pulmonology, 2018, 31, 119-131.	0.3	35
105	Real-Life Patterns of Asthma Controller Use Vary by Age, Time of Day and Season. Journal of Allergy and Clinical Immunology, 2018, 141, AB61.	1.5	3
106	Dr Elliot F. Ellis. Annals of Allergy, Asthma and Immunology, 2018, 121, 3-6.	0.5	0
107	Bringing Technology to Day-to-Day Asthma Management. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 291-292.	2.5	10
108	Improving the global diagnosis and management of asthma in children. Thorax, 2018, 73, 662-669.	2.7	37

#	Article	IF	Citations
109	Future Directions in Asthma Management. , 2018, , 207-209.		O
110	Use of Oral Corticosteroids in the Wheezy Toddler. Journal of Pediatrics, 2018, 201, 16-20.	0.9	4
111	Boehringerâ€Ingelheim Satellite Symposium Choosing the Right Controller Therapy in Pediatric Patients with Asthma. Pediatric Pulmonology, 2018, 53, S171-S173.	1.0	3
112	Tiotropium for the treatment of asthma in adolescents. Expert Opinion on Pharmacotherapy, 2017, 18, 305-312.	0.9	9
113	Race is associated with differences in airway inflammation in patients with asthma. Journal of Allergy and Clinical Immunology, 2017, 140, 257-265.e11.	1.5	39
114	Can we predict fall asthma exacerbations? Validation of the seasonal asthma exacerbation index. Journal of Allergy and Clinical Immunology, 2017, 140, 1130-1137.e5.	1.5	41
115	A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. Journal of Allergy and Clinical Immunology, 2017, 140, 1277-1287.	1.5	101
116	Reply to â€~Can a better patient phenotyping predict the efficacy of tiotropium in asthmatic adolescents?'. Expert Opinion on Pharmacotherapy, 2017, 18, 837-838.	0.9	0
117	Pediatric asthma – moving ahead faster than ever. Current Opinion in Allergy and Clinical Immunology, 2017, 17, 96-98.	1.1	0
118	Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience. Journal of Allergy and Clinical Immunology, 2017, 139, 1431-1444.	1.5	130
119	Current and future management of the young child with early onset wheezing. Current Opinion in Allergy and Clinical Immunology, 2017, 17, 146-152.	1.1	8
120	Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 985-992.	2.5	200
121	Baseline Blood Eosinophils and Reduction of Asthma Exacerbations By Omalizumab in Children with Moderate-to-Severe Allergic Asthma. Journal of Allergy and Clinical Immunology, 2017, 139, AB83.	1.5	2
122	Once-daily Tiotropium Respimat® Add-on Therapy Has a Safety Profile Comparable with Placebo in Children and Adolescents. Journal of Allergy and Clinical Immunology, 2017, 139, AB94.	1.5	3
123	Long-Term Outcomes from a Pediatric Subgroup of Tenor I: 10 Years Follow up. Journal of Allergy and Clinical Immunology, 2017, 139, AB101.	1.5	1
124	Once-daily Tiotropium Respimat $\hat{A}^{@}$ Add-on Therapy Improves Lung Function and Control in Adolescents and Children with Moderate Symptomatic Asthma. Journal of Allergy and Clinical Immunology, 2017, 139, AB95.	1.5	1
125	Building school health partnerships to improve pediatric asthma care: the School-based Asthma Management Program. Current Opinion in Allergy and Clinical Immunology, 2017, 17, 160-166.	1,1	22
126	Does inhaled steroid therapy help emerging asthma in early childhood?. Lancet Respiratory Medicine, the, 2017, 5, 827-834.	5.2	13

#	Article	lF	Citations
127	Reply. Journal of Allergy and Clinical Immunology, 2017, 140, 1213.	1.5	O
128	Author's response. Annals of Allergy, Asthma and Immunology, 2017, 119, 194.	0.5	0
129	Approaching Current and New Drug Therapies for Pediatric Asthma. Pediatric Clinics of North America, 2017, 64, 1197-1207.	0.9	6
130	Stakeholder Perspectives on Optimizing Communication in a School entered Asthma Program. Journal of School Health, 2017, 87, 941-948.	0.8	11
131	Advances in asthma in 2016: Designing individualized approaches to management. Journal of Allergy and Clinical Immunology, 2017, 140, 671-680.	1.5	24
132	The nasal methylome and childhood atopic asthma. Journal of Allergy and Clinical Immunology, 2017, 139, 1478-1488.	1.5	133
133	Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma. Journal of Allergy and Clinical Immunology, 2017, 139, 1489-1495.e5.	1.5	70
134	Examining causes of the urban (inner city) asthma epidemic: Implementing new management strategies. Allergy and Asthma Proceedings, 2016, 37, 4-8.	1.0	4
135	Genetics and Genomics of Longitudinal Lung Function Patterns in Individuals with Asthma. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1465-1474.	2.5	20
136	Salmeterol and Fluticasone Propionate in Children with Asthma. New England Journal of Medicine, 2016, 375, e46.	13.9	4
137	Inhaled corticosteroids. Annals of Allergy, Asthma and Immunology, 2016, 117, 589-594.	0.5	11
138	Tiotropium add-on therapy in adolescents with moderate asthma: AÂ1-year randomized controlled trial. Journal of Allergy and Clinical Immunology, 2016, 138, 441-450.e8.	1.5	133
139	Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. New England Journal of Medicine, 2016, 374, 1842-1852.	13.9	456
140	Creation and implementation of SAMPROâ,,¢: AÂschool-based asthma management program. Journal of Allergy and Clinical Immunology, 2016, 138, 711-723.	1.5	74
141	Leveraging Partnerships: Families, Schools, and Providers Working Together to Improve Asthma Management. Current Allergy and Asthma Reports, 2016, 16, 74.	2.4	17
142	Advances in asthma 2015: Across the lifespan. Journal of Allergy and Clinical Immunology, 2016, 138, 397-404.	1.5	11
143	Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. New England Journal of Medicine, 2016, 375, 840-849.	13.9	116
144	Acetaminophen versus Ibuprofen in Young Children with Mild Persistent Asthma. New England Journal of Medicine, 2016, 375, 619-630.	13.9	60

#	Article	IF	CITATIONS
145	Current application of exhaled nitric oxide in clinical practice. Journal of Allergy and Clinical Immunology, 2016, 138, 1296-1298.	1.5	43
146	Evolution of Asthma Self-Management Programs in Adolescents: From the Crisis Plan to Facebook. Journal of Pediatrics, 2016, 179, 19-23.	0.9	11
147	Individualized therapy for persistent asthma in young children. Journal of Allergy and Clinical Immunology, 2016, 138, 1608-1618.e12.	1.5	208
148	Effect of asthma therapies on the natural course of asthma. Annals of Allergy, Asthma and Immunology, 2016, 117, 627-633.	0.5	15
149	Developing, Implementing, and Evaluating a School-Centered Asthma Program: Step-Up Asthma Program. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 972-979.e1.	2.0	32
150	Omalizumab Decreases Rates of Cold Symptoms in Inner-City Children with Allergic Asthma. Journal of Allergy and Clinical Immunology, 2016, 137, AB87.	1.5	1
151	Asthma Management for Children. Advances in Pediatrics, 2016, 63, 103-126.	0.5	9
152	Creating District Readiness for Implementing Evidence-Based School-Centered Asthma Programs. NASN School Nurse (Print), 2016, 31, 112-118.	0.4	10
153	Intermittent steroid inhalation for the treatment of childhood asthma. Expert Review of Clinical Immunology, 2016, 12, 183-194.	1.3	8
			·
154	New Directions in Asthma Management. , 2016, , 360-364.e1.		0
154 155	New Directions in Asthma Management. , 2016, , 360-364.e1. Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma. , 2016, , .		0
	Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with	1.5	
155	Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma. , 2016, , . Severe Asthma in Pediatric Patients. Pathophysiology and Unmet Needs. Annals of the American	1.5 1.5	1
155 156	Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma. , 2016, , . Severe Asthma in Pediatric Patients. Pathophysiology and Unmet Needs. Annals of the American Thoracic Society, 2016, 13, S103-S104. American Thoracic Society and National Heart, Lung, and Blood Institute Implementation Research		4
155 156 157	Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma., 2016,,. Severe Asthma in Pediatric Patients. Pathophysiology and Unmet Needs. Annals of the American Thoracic Society, 2016, 13, S103-S104. American Thoracic Society and National Heart, Lung, and Blood Institute Implementation Research Workshop Report. Annals of the American Thoracic Society, 2015, 12, S213-S221. Experimentally manipulated sleep duration in adolescents with asthma: Feasibility and preliminary	1.5	1 4 10
155 156 157	Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma., 2016,,. Severe Asthma in Pediatric Patients. Pathophysiology and Unmet Needs. Annals of the American Thoracic Society, 2016, 13, S103-S104. American Thoracic Society and National Heart, Lung, and Blood Institute Implementation Research Workshop Report. Annals of the American Thoracic Society, 2015, 12, S213-S221. Experimentally manipulated sleep duration in adolescents with asthma: Feasibility and preliminary findings. Pediatric Pulmonology, 2015, 50, 1360-1367. Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses. JAMA - Journal of the American Medical	1.5	1 4 10 26
155 156 157 158	Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma., 2016, , . Severe Asthma in Pediatric Patients. Pathophysiology and Unmet Needs. Annals of the American Thoracic Society, 2016, 13, S103-S104. American Thoracic Society and National Heart, Lung, and Blood Institute Implementation Research Workshop Report. Annals of the American Thoracic Society, 2015, 12, S213-S221. Experimentally manipulated sleep duration in adolescents with asthma: Feasibility and preliminary findings. Pediatric Pulmonology, 2015, 50, 1360-1367. Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses. JAMA - Journal of the American Medical Association, 2015, 314, 2034.	1.5 1.0 3.8	1 4 10 26 224

#	Article	IF	CITATIONS
163	Pharmacodynamic genome-wide association study identifies new responsive loci for glucocorticoid intervention in asthma. Pharmacogenomics Journal, 2015, 15, 422-429.	0.9	28
164	DNA methylation and childhood asthma in the inner city. Journal of Allergy and Clinical Immunology, 2015, 136, 69-80.	1.5	189
165	Assessment of Airway Microbiota and Inflammation in Cystic Fibrosis Using Multiple Sampling Methods. Annals of the American Thoracic Society, 2015, 12, 221-229.	1.5	128
166	Airway Obstruction Worsens in Young Adults with Asthma Who Become Obese. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 765-771.e2.	2.0	33
167	Impact of Age and Sex on Response to Asthma Therapy. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 551-558.	2.5	45
168	Monitoring and adherence in asthma management. Lancet Respiratory Medicine, the, 2015, 3, 175-176.	5.2	5
169	A randomised dose-ranging study of tiotropium Respimat $\hat{A}^{@}$ in children with symptomatic asthma despite inhaled corticosteroids. Respiratory Research, 2015, 16, 20.	1.4	77
170	Seasonal risk factors for asthma exacerbations among inner-city children. Journal of Allergy and Clinical Immunology, 2015, 135, 1465-1473.e5.	1.5	143
171	Markers of Differential Response to Inhaled Corticosteroid Treatment Among Children with Mild Persistent Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 540-546.e3.	2.0	25
172	Monitoring asthma in children. European Respiratory Journal, 2015, 45, 906-925.	3.1	114
173	Monitoring asthma in childhood: symptoms, exacerbations and quality of life. European Respiratory Review, 2015, 24, 187-193.	3.0	40
174	Future Research Directions in Asthma. An NHLBI Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1366-1372.	2.5	84
175	New and future strategies to improve asthma control in children. Journal of Allergy and Clinical Immunology, 2015, 136, 848-859.	1.5	80
176	A summary of the new GINA strategy: a roadmap to asthma control. European Respiratory Journal, 2015, 46, 622-639.	3.1	636
177	Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. Journal of Allergy and Clinical Immunology, 2015, 136, 1476-1485.	1.5	452
178	Personalized medicine in children with asthma. Paediatric Respiratory Reviews, 2015, 16, 101-107.	1.2	16
179	Establishing school-centered asthma programs. Journal of Allergy and Clinical Immunology, 2014, 134, 1223-1230.	1.5	54
180	Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. Journal of Allergy and Clinical Immunology, 2014, 134, 560-567.e4.	1.5	194

#	Article	IF	CITATIONS
181	Sleep Duration, Sleep Hygiene, and Insomnia in Adolescents with Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 562-569.	2.0	42
182	Reply. Journal of Allergy and Clinical Immunology, 2014, 133, 1776-1777.	1.5	1
183	The association between vitamin D status andÂthe rate of exacerbations requiring oral corticosteroids in preschool children with recurrent wheezing. Journal of Allergy and Clinical Immunology, 2014, 133, 1489-1492.e3.	1.5	27
184	In lasting tribute: Elliot F. Ellis, MD, 1929-2014. Journal of Allergy and Clinical Immunology, 2014, 133, 1504-1505.	1.5	3
185	Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids. Journal of Allergy and Clinical Immunology, 2014, 133, 664-669.e5.	1.5	70
186	Childhood asthma clusters and response to therapy inÂclinical trials. Journal of Allergy and Clinical Immunology, 2014, 133, 363-369.e3.	1.5	65
187	Advances in pediatric asthma in 2013: Coordinating asthma care. Journal of Allergy and Clinical Immunology, 2014, 133, 654-661.	1.5	21
188	Predictors of asthma control and lung function responsiveness to step 3 therapy in children withÂuncontrolled asthma. Journal of Allergy and Clinical Immunology, 2014, 133, 350-356.	1.5	40
189	Asthma across the ages: Knowledge gaps in childhood asthma. Journal of Allergy and Clinical Immunology, 2014, 133, 3-13.	1.5	78
190	A genome-wide survey of CD4+ lymphocyte regulatory genetic variants identifies novel asthma genes. Journal of Allergy and Clinical Immunology, 2014, 134, 1153-1162.	1.5	46
191	Eczema and race as combined determinants for differential response to step-up asthma therapy. Journal of Allergy and Clinical Immunology, 2014, 134, 483-485.	1.5	25
192	P2X ₇ -Regulated Protection from Exacerbations and Loss of Control Is Independent of Asthma Maintenance Therapy. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 28-33.	2.5	16
193	Reassessment of Omalizumab-Dosing Strategies and Pharmacodynamics in Inner-City Children and Adolescents. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 163-171.	2.0	60
194	Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology, 2013, 132, 1068-1074.e1.	1.5	100
195	Genome-wide association study identifies TH1 pathway genes associated with lung function in asthmatic patients. Journal of Allergy and Clinical Immunology, 2013, 132, 313-320.e15.	1.5	98
196	ITGB5 and AGFG1 variants are associated with severity of airway responsiveness. BMC Medical Genetics, 2013, 14, 86.	2.1	15
197	Advances in pediatric asthma in 2012: Moving toward asthma prevention. Journal of Allergy and Clinical Immunology, 2013, 131, 36-46.	1.5	21
198	Budesonide Inhalation Suspension Versus Montelukast in Children Aged 2 to 4 Years with Mild Persistent Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 58-64.	2.0	19

#	Article	IF	CITATIONS
199	Predictors for Asthma at Age 7 Years for Low-Income Children Enrolled inÂthe Childhood Asthma Prevention Study. Journal of Pediatrics, 2013, 162, 536-542.e2.	0.9	3
200	Inhaled Corticosteroids in Lung Diseases. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 798-803.	2.5	95
201	Integration of Mouse and Human Genome-Wide Association Data Identifies KCNIP4 as an Asthma Gene. PLoS ONE, 2013, 8, e56179.	1.1	28
202	Genome-Wide Association Analysis in Asthma Subjects Identifies SPATS2L as a Novel Bronchodilator Response Gene. PLoS Genetics, 2012, 8, e1002824.	1.5	107
203	Key observations from the NHLBI Asthma Clinical Research Network. Thorax, 2012, 67, 450-455.	2.7	13
204	Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children. Survey of Anesthesiology, 2012, 56, 48.	0.1	13
205	Comparison of Physician-, Biomarker-, and Symptom-Based Strategies for Adjustment of Inhaled Corticosteroid Therapy in Adults With Asthma. JAMA - Journal of the American Medical Association, 2012, 308, 987.	3.8	166
206	Assessment of asthma control and asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) observational cohort. Current Respiratory Care Reports, 2012, 1, 259-269.	0.6	52
207	Evaluation of the National Heart, Lung, and Blood Institute guidelines impairment domain for classifying asthma control and predicting asthma exacerbations. Annals of Allergy, Asthma and Immunology, 2012, 108, 81-87.e3.	0.5	46
208	Adherence to inhaled corticosteroids: An ancillary study of the Childhood Asthma Management Program clinical trial. Journal of Allergy and Clinical Immunology, 2012, 129, 112-118.	1.5	119
209	Advances in pediatric asthma in 2011: Moving forward. Journal of Allergy and Clinical Immunology, 2012, 129, 60-68.	1.5	16
210	The Editors' Choice. Journal of Allergy and Clinical Immunology, 2012, 129, 86-87.	1.5	0
211	The Editors' Choice. Journal of Allergy and Clinical Immunology, 2012, 129, 349-350.	1.5	0
212	Development and validation of the Composite Asthma Severity Index—an outcome measure for use in children and adolescents. Journal of Allergy and Clinical Immunology, 2012, 129, 694-701.	1.5	114
213	Asthma outcomes: Biomarkers. Journal of Allergy and Clinical Immunology, 2012, 129, S9-S23.	1.5	334
214	Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. Journal of Allergy and Clinical Immunology, 2012, 130, 332-342.e10.	1.5	176
215	Early asthma: Stepping closer to primary prevention. Journal of Allergy and Clinical Immunology, 2012, 130, 308-310.	1.5	5
216	The long-acting $\hat{1}^2$ -adrenergic agonist controversy in asthma: Troublesome times!. Journal of Allergy and Clinical Immunology, 2012, 130, 1256-1259.	1.5	6

#	Article	IF	Citations
217	Genome-wide Association Identifies the <i>T</i> Gene as a Novel Asthma Pharmacogenetic Locus. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1286-1291.	2.5	93
218	International consensus on (ICON) pediatric asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 976-997.	2.7	327
219	Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller Trial. Journal of Allergy and Clinical Immunology, 2011, 127, 161-166.e1.	1.5	28
220	Advances in pediatric asthma in 2010: Addressing the major issues. Journal of Allergy and Clinical Immunology, 2011, 127, 102-115.	1.5	24
221	The Editors' Choice. Journal of Allergy and Clinical Immunology, 2011, 127, 1438-1439.	1.5	0
222	The Editors' Choice. Journal of Allergy and Clinical Immunology, 2011, 128, 35-36.	1.5	1
223	The Editors' Choice. Journal of Allergy and Clinical Immunology, 2011, 128, 282-283.	1.5	0
224	Growth of preschool children at high risk for asthma 2 years after discontinuation of fluticasone. Journal of Allergy and Clinical Immunology, 2011, 128, 956-963.e7.	1.5	76
225	Advancing asthma care: The glass is only half full!. Journal of Allergy and Clinical Immunology, 2011, 128, 485-494.	1.5	68
226	Most nocturnal asthma symptoms occur outside of exacerbations and associate with morbidity. Journal of Allergy and Clinical Immunology, 2011, 128, 977-982.e2.	1.5	19
227	The Editors' Choice. Journal of Allergy and Clinical Immunology, 2011, 128, 751-752.	1.5	0
228	Is it time to revise the asthma guidelines?. Journal of Allergy and Clinical Immunology, 2011, 128, 937-938.	1.5	13
229	The Editors' Choice. Journal of Allergy and Clinical Immunology, 2011, 128, 946-947.	1.5	1
230	The Editors' Choice. Journal of Allergy and Clinical Immunology, 2011, 128, 1175.	1.5	0
231	Daily or Intermittent Budesonide in Preschool Children with Recurrent Wheezing. New England Journal of Medicine, 2011, 365, 1990-2001.	13.9	194
232	Economic burden of impairment in children with severe or difficult-to-treat asthma. Annals of Allergy, Asthma and Immunology, 2011, 107, 110-119.e1.	0.5	88
233	New insights into asthma pathogenesis and treatment. Current Opinion in Immunology, 2011, 23, 801-807.	2.4	11
234	Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children. New England Journal of Medicine, 2011, 364, 1005-1015.	13.9	783

#	Article	IF	CITATIONS
235	Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2011, 377, 650-657.	6.3	295
236	Treatment of mild persistent asthma in children – Authors' reply. Lancet, The, 2011, 377, 1744.	6.3	0
237	Personalised medicine for asthma management in pregnancy. Lancet, The, 2011, 378, 963-964.	6.3	3
238	A conceptual framework for pharmacodynamic genome-wide association studies in pharmacogenomics. Drug Discovery Today, 2011, 16, 884-890.	3.2	19
239	The impact of selfâ€identified race on epidemiologic studies of gene expression. Genetic Epidemiology, 2011, 35, 93-101.	0.6	12
240	Genomewide Association between <i>GLCCI1</i> and Response to Glucocorticoid Therapy in Asthma. New England Journal of Medicine, 2011, 365, 1173-1183.	13.9	342
241	Adding LABAs to Inhaled Glucocorticoids for Asthma. New England Journal of Medicine, 2011, 365, 1260-1261.	13.9	2
242	Evaluation of the Impairment Domain Components of the NHLBI Guidelines in Classifying Asthma Control and Predicting Future Asthma Exacerbations. Chest, 2010, 138, 150A.	0.4	0
243	Allergy, total serum immunoglobulin E, and airflow in children and adolescents in TENOR. Pediatric Allergy and Immunology, 2010, 21, 1157-1165.	1.1	33
244	Mapping of numerous disease-associated expression polymorphisms in primary peripheral blood CD4+ lymphocytes. Human Molecular Genetics, 2010, 19, 4745-4757.	1.4	98
245	Lessons learned from variation in response to therapy in clinical trials. Journal of Allergy and Clinical Immunology, 2010, 125, 285-292.	1.5	44
246	Predictors of remitting, periodic, and persistent childhood asthma. Journal of Allergy and Clinical Immunology, 2010, 125, 359-366.e3.	1.5	93
247	Advances in pediatric asthma in 2009: Gaining control of childhood asthma. Journal of Allergy and Clinical Immunology, 2010, 125, 69-78.	1.5	18
248	Achieving asthma control in the inner city: Do the National Institutes of Health Asthma Guidelines really work?. Journal of Allergy and Clinical Immunology, 2010, 125, 521-526.	1.5	41
249	Asthma control, adiposity, and adipokines among inner-city adolescents. Journal of Allergy and Clinical Immunology, 2010, 125, 584-592.	1.5	169
250	Forced expiratory flow between 25% and 75% of vital capacity and FEV1/forced vital capacity ratio in relation to clinical and physiological parameters in asthmatic children with normal FEV1 values. Journal of Allergy and Clinical Immunology, 2010, 126, 527-534.e8.	1.5	149
251	Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma. Journal of Allergy and Clinical Immunology, 2010, 126, 545-551.e4.	1.5	65
252	The Editors' Choice. Journal of Allergy and Clinical Immunology, 2010, 126, 481-482.	1.5	8

#	Article	IF	Citations
253	Defining asthma phenotypes: Focusing the picture. Journal of Allergy and Clinical Immunology, 2010, 126, 939-940.	1.5	6
254	Step-up Therapy for Children with Uncontrolled Asthma Receiving Inhaled Corticosteroids. New England Journal of Medicine, 2010, 362, 975-985.	13.9	406
255	Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma. New England Journal of Medicine, 2010, 363, 1715-1726.	13.9	467
256	A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology, 2010, 126, 747-753.	1.5	128
257	Guidelines for the Treatment of Childhood Asthma. , 2010, , 348-353.		0
258	New Directions in Asthma Management. , 2010, , 463-470.		0
259	An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 59-99.	2.5	1,591
260	Predictors of poor response during asthma therapy differ with definition of outcome. Pharmacogenomics, 2009, 10, 1231-1242.	0.6	54
261	Long-Term Budesonide or Nedocromil Treatment, Once Discontinued, Does Not Alter the Course of Mild to Moderate Asthma in Children and Adolescents. Journal of Pediatrics, 2009, 154, 682-687.e7.	0.9	92
262	Impulse oscillometry versus spirometry in a long-term study of controller therapy for pediatric asthma. Journal of Allergy and Clinical Immunology, 2009, 123, 861-867.e1.	1.5	92
263	Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma. Journal of Allergy and Clinical Immunology, 2009, 123, 411-416.	1.5	107
264	Patient characteristics associated with improved outcomes with use of an inhaled corticosteroid in preschool children at risk for asthma. Journal of Allergy and Clinical Immunology, 2009, 123, 1077-1082.e5.	1.5	82
265	Asthma morbidity among inner-city adolescents receiving guidelines-based therapy: Role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology, 2009, 124, 213-221.e1.	1.5	28
266	Managing asthma and allergies in schools: An opportunity to coordinate health care. Journal of Allergy and Clinical Immunology, 2009, 124, 201-204.	1.5	7
267	Does access to care equal asthma control in school-age children?. Journal of Allergy and Clinical Immunology, 2009, 124, 381-383.	1.5	3
268	Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. Journal of Allergy and Clinical Immunology, 2009, 124, 895-902.e4.	1.5	160
269	Recent asthma exacerbations predict future exacerbations in children with severe or difficult-to-treat asthma. Journal of Allergy and Clinical Immunology, 2009, 124, 921-927.	1.5	112
270	Baseline characteristics of patients enrolled in EXCELS: a cohort study. Annals of Allergy, Asthma and Immunology, 2009, 103, 212-219.	0.5	50

#	Article	IF	CITATIONS
271	Effect of Î ² 2-adrenergic receptor polymorphism on response to longacting Î ² 2 agonist in asthma (LARGE) Tj ETQq1 1754-1764.	1 0.7843 6.3	14 rgBT / 213
272	Advances in pediatric asthma in 2008: Where do we go now?. Journal of Allergy and Clinical Immunology, 2009, 123, 28-34.	1.5	7
273	Correlates of Household Smoking Bans in Low-Income Families of Children With and Without Asthma. Family Process, 2008, 47, 81-94.	1.4	24
274	Advances in pediatric asthma in 2007. Journal of Allergy and Clinical Immunology, 2008, 121, 614-619.	1.5	7
275	Asthma progression: Can we and should we measure it?. Journal of Allergy and Clinical Immunology, 2008, 121, 598-600.	1.5	6
276	Factors associated with asthma exacerbations during a long-term clinical trial of controller medications in children. Journal of Allergy and Clinical Immunology, 2008, 122, 741-747.e4.	1.5	157
277	Asthma exacerbations: Putting a lid on the volcano. Journal of Allergy and Clinical Immunology, 2008, 122, 697-699.	1.5	3
278	Clinical predictors and outcomes of consistent bronchodilator response in the childhood asthma management program. Journal of Allergy and Clinical Immunology, 2008, 122, 921-928.e4.	1.5	70
279	Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. Journal of Allergy and Clinical Immunology, 2008, 122, 1127-1135.e8.	1.5	242
280	Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet, The, 2008, 372, 1065-1072.	6.3	414
281	Azithromycin or montelukast as inhaled corticosteroid–sparing agents in moderate-to-severe childhood asthma study. Journal of Allergy and Clinical Immunology, 2008, 122, 1138-1144.e4.	1.5	125
282	Individualizing Asthma Therapy: Application of Biomarkers. Journal of Asthma, 2008, 45, 29-31.	0.9	2
283	Singleâ€Dose Pharmacokinetics of Roflumilast in Children and Adolescents. Journal of Clinical Pharmacology, 2008, 48, 978-985.	1.0	10
284	Combination Therapy with a Long-Acting \hat{l}^2 -Agonist and a Leukotriene Antagonist in Moderate Asthma. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 228-234.	2.5	74
285	Smoking Affects Response to Inhaled Corticosteroids or Leukotriene Receptor Antagonists in Asthma. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 783-790.	2.5	382
286	Steroid therapy for asthma in children. Current Opinion in Pediatrics, 2007, 19, 300-305.	1.0	2
287	Advances in pediatric asthma 2006. Journal of Allergy and Clinical Immunology, 2007, 119, 558-562.	1.5	9
288	Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial. Journal of Allergy and Clinical Immunology, 2007, 119, 64-72.	1.5	275

#	Article	IF	CITATIONS
289	The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. Journal of Allergy and Clinical Immunology, 2007, 119, 73-80.	1.5	170
290	A view from the bus: On the roadmap with the National Institutes of Health Asthma Networks. Journal of Allergy and Clinical Immunology, 2007, 119, 24-27.	1.5	5
291	Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. Journal of Allergy and Clinical Immunology, 2007, 119, 1156-1163.	1.5	82
292	Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. Journal of Allergy and Clinical Immunology, 2007, 120, 1043-1050.	1.5	106
293	Prevalence of asthma-like symptoms in young children. Pediatric Pulmonology, 2007, 42, 723-728.	1.0	237
294	\hat{l}^2 -Adrenergic Receptor Polymorphisms and Response to Salmeterol. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 519-526.	2.5	293
295	Effect of montelukast on peripheral airflow obstruction in children with asthma. Annals of Allergy, Asthma and Immunology, 2006, 96, 541-549.	0.5	42
296	Corticosteroid Therapy in Asthma: Predictors of Responsiveness. Clinics in Chest Medicine, 2006, 27, 119-132.	0.8	22
297	Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. Journal of Allergy and Clinical Immunology, 2006, 117, 45-52.	1.5	236
298	"Black box―warning: Wake-up call or overreaction?. Journal of Allergy and Clinical Immunology, 2006, 117, 26-29.	1.5	16
299	Managing severe asthma. Journal of Allergy and Clinical Immunology, 2006, 117, 508-511.	1.5	28
300	Advances in adult and pediatric asthma. Journal of Allergy and Clinical Immunology, 2006, 117, 512-518.	1.5	35
301	Bronchodilation and bronchoconstriction: Predictors of future lung function in childhood asthma. Journal of Allergy and Clinical Immunology, 2006, 117, 1264-1271.	1.5	94
302	Mild to moderate asthma affects lung growth in children and adolescents. Journal of Allergy and Clinical Immunology, 2006, 118, 1040-1047.	1.5	141
303	Long-Term Inhaled Corticosteroids in Preschool Children at High Risk for Asthma. New England Journal of Medicine, 2006, 354, 1985-1997.	13.9	931
304	Daily versus As-Needed Corticosteroids for Mild Persistent Asthma. New England Journal of Medicine, 2005, 352, 1519-1528.	13.9	363
305	Airway Remodeling. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 672-673.	2.5	11
306	Ciclesonide, a Novel Inhaled Steroid, Does Not Affect Hypothalamic-Pituitary-Adrenal Axis Function in Patients With Moderate-to-Severe Persistent Asthma. Chest, 2005, 128, 1104-1114.	0.4	99

#	Article	IF	Citations
307	Oral corticosteroids in poorly controlled asthma. Journal of Allergy and Clinical Immunology, 2005, 115, 200-201.	1.5	14
308	Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. Journal of Allergy and Clinical Immunology, 2005, 115, 233-242.	1.5	545
309	Understanding mild persistent asthma in children: The next frontier. Journal of Allergy and Clinical Immunology, 2005, 115, 708-713.	1.5	31
310	Advances in pediatric and adult asthma. Journal of Allergy and Clinical Immunology, 2005, 115, 470-477.	1.5	36
311	Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. Journal of Allergy and Clinical Immunology, 2005, 115, 720-727.	1.5	175
312	Facing the challenges of childhood asthma: What changes are necessary?. Journal of Allergy and Clinical Immunology, 2005, 115, 685-688.	1.5	15
313	Progression of asthma in childhood. Journal of Allergy and Clinical Immunology, 2005, 115, 700-707.	1.5	22
314	Fluticasone propionate plasma concentration and systemic effect: Effect of delivery device and duration of administration. Journal of Allergy and Clinical Immunology, 2005, 116, 525-530.	1.5	26
315	Progression of Asthma Measured by Lung Function in the Childhood Asthma Management Program. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 234-241.	2.5	205
316	The Prevention of Early Asthma in Kids study: design, rationale and methods for the Childhood Asthma Research and Education network. Contemporary Clinical Trials, 2004, 25, 286-310.	2.0	160
317	Analyzing asthma phenotypes. Journal of Allergy and Clinical Immunology, 2004, 113, 1-1.	1.5	9
318	Assessing asthma controlBeyond the FEV1. Journal of Allergy and Clinical Immunology, 2004, 113, 2-2.	1.5	29
319	Advances in adult and pediatric asthma. Journal of Allergy and Clinical Immunology, 2004, 113, 407-414.	1.5	26
320	The beneficial effect of dog exposure is modified by genetic phenotype. Journal of Allergy and Clinical Immunology, 2004, 113, 187-187.	1.5	2
321	Genes, farmers, and asthma. Journal of Allergy and Clinical Immunology, 2004, 113, 371.	1.5	0
322	IL-9. Journal of Allergy and Clinical Immunology, 2004, 113, 372.	1.5	1
323	The immune response in human beings to Amb a 1 linked to ISS DNA. Journal of Allergy and Clinical Immunology, 2004, 113 , 1011 - 1011 .	1.5	0
324	Reduced glucocorticoid receptor translocation in steroid-insensitive asthma. Journal of Allergy and Clinical Immunology, 2004, 113, 1012-1012.	1.5	0

#	Article	IF	CITATIONS
325	Safety and application of induced sputum analysis in childhood asthma. Journal of Allergy and Clinical Immunology, 2004, 114, 575-582.	1.5	102
326	The Aerocrine exhaled nitric oxide monitoring system NIOX is cleared by the US Food and Drug Administration for monitoring therapy in asthma. Journal of Allergy and Clinical Immunology, 2004, 114, 1241-1256.	1.5	150
327	Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma. Journal of Allergy and Clinical Immunology, 2004, 114, 1282-1287.	1.5	346
328	Safety profile of budesonide inhalation suspension in the pediatric population: worldwide experience. Annals of Allergy, Asthma and Immunology, 2004, 93, 83-90.	0.5	23
329	Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet, The, 2004, 364, 1505-1512.	6.3	592
330	Current concepts in asthma treatment in children. Current Opinion in Pediatrics, 2004, 16, 299-304.	1.0	4
331	Risk-Benefit Value of Inhaled Glucocorticoids: A Pharmacokinetic/ Pharmacodynamic Perspective. Journal of Clinical Pharmacology, 2004, 44, 37-47.	1.0	83
332	The need for pediatric studies of allergy and asthma medications. Current Allergy and Asthma Reports, 2003, 3, 478-483.	2.4	3
333	Role of budesonide as maintenance therapy for children with asthma. Pediatric Pulmonology, 2003, 36, 13-21.	1.0	3
334	First do no harm: Managing antihistamine impairment in patients with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2003, 111, S835-S842.	1.5	123
335	Advances in childhood asthma: Hygiene hypothesis, natural history, and management. Journal of Allergy and Clinical Immunology, 2003, 111, S785-S792.	1.5	44
336	Minimizing attrition in a long-term clinical trial of pediatric asthma. Annals of Allergy, Asthma and Immunology, 2003, 91, 168-176.	0.5	32
337	Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. Journal of Allergy and Clinical Immunology, 2003, 112, 883-892.	1.5	294
338	Exhaled nitric oxide. Journal of Allergy and Clinical Immunology, 2003, 112, 817.	1.5	2
339	A possible new role for blocking antibody. Journal of Allergy and Clinical Immunology, 2003, 112, 818.	1.5	0
340	Fish oil intervention to prevent infant allergy. Journal of Allergy and Clinical Immunology, 2003, 112, 1020.	1.5	0
341	Sorting out the messages from \hat{I}^2 2-adrenergic receptor polymorphisms. Journal of Allergy and Clinical Immunology, 2003, 112, 1019.	1.5	0
342	Inhaled Corticosteroids. Journal of Allergy and Clinical Immunology, 2003, 112, S1-S40.	1.5	211

#	Article	IF	Citations
343	Relations between exhaled nitric oxide and measures of disease activity among children with mild-to-moderate asthma. Journal of Pediatrics, 2003, 142, 469-475.	0.9	145
344	Growth and bone density in children with mild-moderate asthma: A cross-sectional study in children entering the Childhood Asthma Management Program (CAMP). Journal of Pediatrics, 2003, 142, 286-291.	0.9	39
345	Efficacy and Safety of Extrafine Beclomethasone Dipropionate Aerosol Therapy in Children with Asthma: A Twelve-Week Placebo-Controlled Trial. Pediatric Asthma, Allergy and Immunology, 2003, 16, 1-13.	0.2	4
346	Pediatric Asthma. Chest, 2003, 123, 434S-438S.	0.4	4
347	Histopathology of Severe Childhood Asthma. Chest, 2003, 124, 32-41.	0.4	162
348	Montelukast for Respiratory Syncytial Virus Bronchiolitis. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 290-291.	2.5	15
349	Systematic Review of the Evidence Regarding Potential Complications of Inhaled Corticosteroid Use in Asthma. Chest, 2003, 124, 2329-2340.	0.4	104
350	A Comparison of the Clinical Characteristics of Children and Adults With Severe Asthma. Chest, 2003, 124, 1318-1324.	0.4	134
351	Airway Tissue Mast Cells in Persistent Asthma. Chest, 2003, 124, 42-50.	0.4	33
352	Steroid-Unresponsive Asthma. Seminars in Respiratory and Critical Care Medicine, 2002, 23, 387-398.	0.8	30
353	Inhaled Steroids: Are They All Created Equal?. Seminars in Respiratory and Critical Care Medicine, 2002, 23, 377-386.	0.8	0
354	Growth, Systemic Safety, and Efficacy During 1 Year of Asthma Treatment With Different Beclomethasone Dipropionate Formulations: An Open-Label, Randomized Comparison of Extrafine and Conventional Aerosols in Children. Pediatrics, 2002, 109, e92-e92.	1.0	56
355	Nebulized Budesonide Inhalation Suspension Compared With Cromolyn Sodium Nebulizer Solution for Asthma in Young Children: Results of a Randomized Outcomes Trial. Pediatrics, 2002, 109, 866-872.	1.0	79
356	Efficacy of beclomethasone dipropionate (BDP) extrafine aerosol following switch from conventional BDP in children with asthma. Journal of Allergy and Clinical Immunology, 2002, 109, S246-S246.	1.5	0
357	Systemic Effect Comparisons of Six Inhaled Corticosteroid Preparations. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1377-1383.	2.5	248
358	Childhood asthma: New insights into management. Journal of Allergy and Clinical Immunology, 2002, 109, 3-13.	1.5	38
359	Significant variability in response to inhaled corticosteroids for persistent asthma. Journal of Allergy and Clinical Immunology, 2002, 109, 410-418.	1.5	575
360	Budesonide inhalation suspension: A nebulized corticosteroid for persistent asthma. Journal of Allergy and Clinical Immunology, 2002, 109, 729-742.	1.5	50

#	Article	IF	CITATIONS
361	Altering the course of asthma: Introduction. Journal of Allergy and Clinical Immunology, 2002, 109, S519-S520.	1.5	4
362	The natural history of asthma and early intervention. Journal of Allergy and Clinical Immunology, 2002, 109, S549-S553.	1.5	21
363	Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: A 6-month, open- label, randomized trial. Journal of Allergy and Clinical Immunology, 2002, 110, 45-50.	1.5	27
364	Nocturnal awakening caused by asthma in children with mild-to-moderate asthma in the childhood asthma management program. Journal of Allergy and Clinical Immunology, 2002, 110, 395-403.	1.5	95
365	Prevalence and correlates of household exposures to tobacco smoke and pets in children with asthma. Journal of Pediatrics, 2002, 141, 109-115.	0.9	31
366	Medication Labeling for Children: Where is it Going?. Journal of Pediatric Gastroenterology and Nutrition, 2002, 35, 111-112.	0.9	1
367	Challenges in assessing outcomes for pediatric asthma. Journal of Allergy and Clinical Immunology, 2001, 107, S456-S464.	1.5	27
368	Pharmacokinetics of intranasal corticosteroids. Journal of Allergy and Clinical Immunology, 2001, 108, S26-S31.	1.5	87
369	The Editors' Choice. Journal of Allergy and Clinical Immunology, 2001, 108, 155-156.	1.5	0
370	The Editors' Choice. Journal of Allergy and Clinical Immunology, 2001, 108, 315-316.	1.5	0
371	Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study. Annals of Allergy, Asthma and Immunology, 2001, 87, 501-505.	0.5	66
372	A Review of Budesonide Inhalation Suspension in the Treatment of Pediatric Asthma. Pharmacotherapy, 2001, 21, 195-206.	1.2	14
373	Effect of Polymorphism of the \hat{l}^2 sub>2-Adrenergic Receptor on Response to Regular Use of Albuterol in Asthma. International Archives of Allergy and Immunology, 2001, 124, 183-186.	0.9	102
374	The Utility of Peak Flow, Symptom Scores, and \hat{l}^2 -Agonist Use as Outcome Measures in Asthma Clinical Research. Chest, 2001, 119, 1027-1033.	0.4	27
375	Long-Term Effects of Budesonide or Nedocromil in Children with Asthma. New England Journal of Medicine, 2000, 343, 1054-1063.	13.9	1,376
376	Measurement of children's asthma medication adherence by self report, mother report, canister weight, and Doser CT. Annals of Allergy, Asthma and Immunology, 2000, 85, 416-421.	0.5	339
377	Meeting the needs of the modernization act: Challenges in developing pediatric therapies. Journal of Allergy and Clinical Immunology, 2000, 106, S115-S117.	1.5	5
378	Perception of induced bronchoconstriction in a community sample of adolescents. Journal of Allergy and Clinical Immunology, 2000, 106, 1102-1107.	1.5	13

#	Article	IF	CITATIONS
379	Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. Journal of Allergy and Clinical Immunology, 2000, 106, 1209-1226.	1.5	140
380	The Editors' Choice. Journal of Allergy and Clinical Immunology, 2000, 105, 1039-1040.	1.5	2
381	The Editors' Choice. Journal of Allergy and Clinical Immunology, 2000, 105, 191-192.	1.5	O
382	Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma. Journal of Allergy and Clinical Immunology, 2000, 105, 259-268.	1.5	85
383	CORTICOSTEROID-INSENSITIVE ASTHMA. Immunology and Allergy Clinics of North America, 1999, 19, 837-853.	0.7	0
384	The relationships among environmental allergen sensitization, allergen exposure, pulmonary function, and bronchial hyperresponsiveness in the Childhood Asthma Management Program. Journal of Allergy and Clinical Immunology, 1999, 104, 775-785.	1.5	173
385	Clinical outcomes of steroid-insensitive asthma. Annals of Allergy, Asthma and Immunology, 1999, 83, 55-60.	0.5	16
386	Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Annals of Allergy, Asthma and Immunology, 1999, 83, 231-239.	0.5	133
387	The Editors' Choice. Journal of Allergy and Clinical Immunology, 1999, 104, 1117-1118.	1.5	1
388	Increased T-cell receptor VÎ ² 8+ T cells in bronchoalveolar lavage fluid of subjects with poorly controlled asthma: A potential role for microbial superantigensâ~†â~†â~†â~ Journal of Allergy and Clinical Immunology, 1999, 104, 37-45.	1.5	70
389	Reliability of the model MC-311 MDI Chronologâ~†â~†â~†â~ Journal of Allergy and Clinical Immunology, 1999, 10 53-57.	¹⁴ 1.5	51
390	Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. Journal of Allergy and Clinical Immunology, 1999, 103, 1031-1035.	1.5	104
391	The editors' choice. Journal of Allergy and Clinical Immunology, 1999, 104, 715-716.	1.5	O
392	The Editor's Choiceâ~†. Journal of Allergy and Clinical Immunology, 1999, 104, 249-250.	1.5	1
393	Time to onset of effect of fluticasone propionate in patients with asthma. Journal of Allergy and Clinical Immunology, 1999, 103, 780-788.	1.5	48
394	Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. Journal of Allergy and Clinical Immunology, 1999, 103, 421-426.	1.5	123
395	Immunologic Basis and Management of Steroid-Resistant Asthma. Allergy and Asthma Proceedings, 1999, 20, 9-14.	1.0	25
396	Bone Mineral Density in Children With Asthma Receiving Long-TermTreatment with Inhaled Budesonide. Pediatrics, 1999, 104, 390-391.	1.0	0

#	Article	IF	CITATIONS
397	New insights into steroid resistant asthma. Pediatric Allergy and Immunology, 1998, 9, 3-12.	1.1	29
398	Mechanisms of Glucocorticoid-Resistant Asthmaa. Annals of the New York Academy of Sciences, 1998, 840, 735-746.	1.8	60
399	Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. Journal of Pediatrics, 1998, 132, 976-982.	0.9	110
400	PHARMACOLOGIC MANAGEMENT OF PEDIATRIC ASTHMA. Immunology and Allergy Clinics of North America, 1998, 18, 165-181.	0.7	2
401	Fluticasone Propionate Results in Improved Glucocorticoid Receptor Binding Affinity and Reduced Oral Glucocorticoid Requirements in Severe Asthma. Annals of Allergy, Asthma and Immunology, 1998, 81, 35-40.	0.5	20
402	Alternative agents for anti-inflammatory treatment of asthma. Journal of Allergy and Clinical Immunology, 1998, 102, S23-S35.	1.5	33
403	Early intervention for childhood asthma: Inhaled glucocorticoids as the "preferred―medicationâ~†â~†â~†. Journal of Allergy and Clinical Immunology, 1998, 102, 719-721.	1.5	12
404	Leukotriene modifiers: What is their position in asthma therapy?. Journal of Allergy and Clinical Immunology, 1998, 102, 170-172.	1.5	12
405	Difficult-to-control asthma: Clinical characteristics of steroid-insensitive asthma⯆⯆⯆â¯â¯â¯ã ournal of Alland Clinical Immunology, 1998, 101, 594-601.	ergy 1.3	175
406	New Insights into the Pathogenesis and Management of Steroid-Resistant Asthma. Journal of Asthma, 1997, 34, 177-194.	0.9	23
407	The safety of inhaled corticosteroid therapy in children. Current Opinion in Pediatrics, 1997, 9, 585-589.	1.0	8
408	DIAGNOSIS AND MANAGEMENT OF STEROID-RESISTANT ASTHMA. Clinics in Chest Medicine, 1997, 18, 611-625.	0.8	12
409	Association of Glucocorticoid Insensitivity with Increased Expression of Glucocorticoid Receptor \hat{l}^2 . Journal of Experimental Medicine, 1997, 186, 1567-1574.	4.2	406
410	Comparison of exhaled nitric oxide, serum eosinophilic cationic protein, and soluble interleukin-2 receptor in exacerbations of pediatric asthma., 1997, 24, 305-311.		65
411	Steroid-Resistant Asthma: Evaluation and Management. Annals of Allergy, Asthma and Immunology, 1996, 77, 345-356.	0.5	24
412	The etiology and control of bronchial hyperresponsiveness in children. Current Opinion in Pediatrics, 1996, 8, 591-596.	1.0	12
413	Induction of Corticosteroid Resistance <i>In Vitro</i> . American Journal of Respiratory and Critical Care Medicine, 1996, 154, S34-S38.	2.5	2
414	Comparison of Regularly Scheduled with As-Needed Use of Albuterol in Mild Asthma. New England Journal of Medicine, 1996, 335, 841-847.	13.9	352

#	Article	IF	CITATIONS
415	HIV-1 MESSENGER RNA IN PERIPHERAL BLOOD MONONUCLEAR CELLS AS AN EARLY MARKER OF RISK FOR PROGRESSION TO AIDS. Pediatrics, 1996, 98, 343-343.	1.0	O
416	Chronotherapy of asthma with inhaled steroids: The effect of dosage timing on drug efficacy. Journal of Allergy and Clinical Immunology, 1995, 95, 1172-1178.	1.5	126
417	Management of Steroid-Resistant Asthma. BioDrugs, 1995, 4, 124-137.	0.7	4
418	Evolving role of theophylline for treatment of chronic childhood asthma. Journal of Pediatrics, 1995, 127, 176-185.	0.9	27
419	Coexistence of glucocorticoid receptor and pharmacokinetic abnormalities: Factors that contribute to a poor response to treatment with glucocorticoids in children with asthma. Journal of Pediatrics, 1994, 124, 984-986.	0.9	19
420	Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology, 1993, 91, 873-882.	1.5	94
421	Alternative Treatments for Asthma: Assessing the Need. Journal of Asthma, 1992, 29, 91-97.	0.9	13
422	Alternative Therapy in Severe Asthma: Review Article. Journal of Asthma, 1992, 29, 3-11.	0.9	8
423	Asthma Pathogenesis and the Implications for Therapy in Children. Pediatric Clinics of North America, 1992, 39, 1205-1224.	0.9	4
424	Management of Chronic Asthma. Pediatric Clinics of North America, 1992, 39, 1293-1310.	0.9	12
425	Adrenal Function in Adult Asthmatics during Long-term Daily Treatment with 800, 1,200, and 1,600 μg Triamcinolone Acetonide. Chest, 1992, 101, 1250-1256.	0.4	16
426	Anti-inflammatory drugs in the treatment of allergic disease. Medical Clinics of North America, 1992, 76, 953-975.	1.1	18
427	Clinical Acumen: Brief Report: Therapeutic Manipulations in Severe Nocturnal Asthma. A Nonconventional Approach in a Severe High-Risk Asthmatic. Journal of Asthma, 1992, 29, 281-287.	0.9	3
428	Altered prednisolone pharmacokinetics in patients with cystic fibrosis. Journal of Pediatrics, 1992, 120, 789-794.	0.9	29
429	Safety and efficacy of theophylline in children with asthma. Journal of Pediatrics, 1992, 120, 177-183.	0.9	65
430	High-dose systemic glucocorticoid therapy in the treatment of severe asthma: A case of resistance and patterns of response. Journal of Allergy and Clinical Immunology, 1992, 90, 685-687.	1.5	24
431	Inhaled glucocorticoid therapy in children: How much is safe?. Pediatric Pulmonology, 1992, 12, 71-72.	1.0	27
432	Inhaled therapy in infants: Why not nebulize glucocorticoids?. Pediatric Pulmonology, 1992, 13, 198-199.	1.0	10

#	Article	IF	Citations
433	Steroid resistance in asthma: Our current understanding. Pediatric Pulmonology, 1992, 14, 180-186.	1.0	15
434	Editorial reply: Inhaled glucocorticoid therapy. Pediatric Pulmonology, 1992, 14, 197-198.	1.0	0
435	Plasma histamine, epinephrine, cortisol, and leukocyte \hat{l}^2 -adrenergic receptors in nocturnal asthma. Clinical Pharmacology and Therapeutics, 1991, 49, 59-68.	2.3	101
436	Psychological change associated with theophylline treatment of asthmatic children: A 6-month study. Pediatric Pulmonology, 1991, 11, 233-242.	1.0	21
437	Regular Inhaled Beta-Adrenergic Agonists in the Treatment of Bronchial Asthma: Beneficial or Detrimental?. The American Review of Respiratory Disease, 1991, 144, 249-250.	2.9	46
438	A Comparison of Aerosol Glucocorticoids in the Treatment of Chronic Bronchial Asthma. Pediatric Asthma, Allergy and Immunology, 1991, 5, 227-235.	0.2	9
439	Airways Inflammation in Nocturnal Asthma. The American Review of Respiratory Disease, 1991, 143, 351-357.	2.9	283
440	Efficacy of Atropine Methylnitrate Alone and in Combination with Albuterol in Children with Asthma. Chest, 1990, 98, 637-642.	0.4	17
441	Monitoring glucocorticoid therapy: A pharmacokinetic approach. Clinical Pharmacology and Therapeutics, 1990, 48, 390-398.	2.3	95
442	Measuring the response to glucocorticoids. Journal of Allergy and Clinical Immunology, 1990, 85, 985-987.	1.5	12
443	Regarding the article by Furukawa et al. Journal of Allergy and Clinical Immunology, 1989, 83, 1141-1142.	1.5	2
444	The use of antihistamines in patients with asthma. Journal of Allergy and Clinical Immunology, 1988, 82, 481-482.	1.5	22
445	438 Penetration of systemic corticosteroids into the lung; A difference between prednisolone and methylprednisolone. Journal of Allergy and Clinical Immunology, 1988, 81, 277.	1.5	0
446	Sustained Release Theophylline Preparations. Drugs, 1988, 35, 711-726.	4.9	12
447	The Consistency of Theophylline Absorption from a Sustainedâ€Release Formulation in Asthmatic Children. Pharmacotherapy, 1988, 8, 277-283.	1.2	1
448	Theophylline Absorption from Two Sustained-Release Products: Implications for Therapeutic Drug Monitoring. The American Review of Respiratory Disease, 1987, 136, 1168-1174.	2.9	8
449	Effects of theophylline on learning and behavior: Reason for concern or concern without reason?. Journal of Pediatrics, 1987, 111, 471-474.	0.9	47
450	Effects of cell isolation procedures and radioligand selection on the characterization of human leukocyte \hat{l}^2 -adrenergic receptors. Biochemical Pharmacology, 1987, 36, 1589-1597.	2.0	18

#	Article	IF	Citations
451	Corticosteroid therapy in adolescent patients. Journal of Adolescent Health Care: Official Publication of the Society for Adolescent Medicine, 1987, 8, 84-91.	0.3	3
452	Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. Clinical Pharmacology and Therapeutics, 1987, 42, 424-432.	2.3	76
453	Workshop 2: Special pharmacologic considerations. Journal of Allergy and Clinical Immunology, 1986, 78, 498-506.	1.5	0
454	Theophylline absorption in young asthmatic children receiving sustained-release formulations. Journal of Pediatrics, 1985, 107, 805-810.	0.9	25
455	Inconsistent absorption from a susstained-release theophylline preparation during continuous therapy in asthmatic children. Journal of Pediatrics, 1985, 106, 496-501.	0.9	53
456	Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Journal of Allergy and Clinical Immunology, 1985, 75, 443-449.	1.5	48
457	Analysis of cortisol, methylprednisolone, and methylprednisolone hemisuccinate. Biomedical Applications, 1984, 305, 271-280.	1.7	60
458	Drug abuse and the asthmatic patient: A case report. Journal of Allergy and Clinical Immunology, 1984, 74, 201-204.	1.5	3
459	Comparison of inter- and intra-subject variation in oral absorption of theophylline from sustained-release products. International Journal of Pharmaceutics, 1984, 21, 3-16.	2.6	11
460	Effect of inflammatory bowel disease on absorption and disposition of prednisolone. Digestive Diseases and Sciences, 1983, 28, 161-168.	1.1	28
461	Prednisolone Disposition and Protein Binding in Oral Contraceptive Users*. Journal of Clinical Endocrinology and Metabolism, 1983, 56, 702-709.	1.8	59
462	Practical Considerations in the Safe and Effective Use of Theophylline. Pediatric Clinics of North America, 1983, 30, 943-954.	0.9	7
463	Dose- and time-related effect of troleandomycin on methylprednisolone elimination. Clinical Pharmacology and Therapeutics, 1982, 32, 166-171.	2.3	58
464	The effect of troleandomycin on methylprednisolone elimination. Journal of Allergy and Clinical Immunology, 1980, 66, 447-451.	1.5	131
465	Relationship of gentamicin serum concentrations to gestational age in preterm and term neonates. Journal of Pediatrics, 1980, 97, 312-315.	0.9	73
466	Paradoxical behavior of serum digoxin concentrations in an anuric neonate. Journal of Pediatrics, 1977, 91, 487-489.	0.9	9
467	Pharmacokinetic Design of Digoxin Dosage Regimens in Relation to Renal Function. Journal of Clinical Pharmacology, 1974, 14, 525-535.	1.0	67